

ESG in Life Sciences Partnerships: A Primer

A UK-China Perspective on Responsible Innovation

Prepared by Excellence First Enterprise Consultancy (EFEC)

Introduction: Why ESG Matters in Cross-Border Life Sciences

In life sciences, innovation is not only about scientific discovery or commercial success—it directly impacts patients, ecosystems, and public trust. In this context, Environmental, Social, and Governance (ESG) principles are now considered foundations of credible and sustainable collaboration.

For UK and China, two of the world's most dynamic and complementary innovation ecosystems, ESG is not an optional extra. Cross-border partnerships face heightened scrutiny, from differing regulatory systems to cultural expectations. ESG provides the framework that allows collaborations to move beyond transactions and become long-term, trusted relationships.

What ESG Means in Life Sciences



Environmental

- › **Clinical trial sustainability:** reducing travel footprints, minimising waste, and adopting greener logistics.
- › **Greener labs:** adopting low-energy equipment, sustainable sourcing, and environmentally friendly practices.
- › **Transparent supply chains:** ensuring vendors and partners align with international green standards.



Social

- › **Fairness in partnerships:** equitable terms for both SMEs and larger institutions.
- › **Patient-centred outcomes:** prioritising patient safety, accessibility, and public health relevance.
- › **Workforce inclusion:** ensuring diverse, inclusive teams across research, clinical, and commercial levels.



Governance

- › **Data integrity:** applying rigorous stewardship, transparency, and accountability in cross-border trials.
- › **Intellectual property protection:** securing and respecting IP rights in both UK and China.
- › **AI/Biotech ethics:** embedding algorithmic transparency, informed consent, and ethical compliance in advanced technologies.



Cross-Border Ethics: UK–China Partnerships

Cross-border collaboration between the UK and China magnifies the importance of ESG, as companies must align across different legal, regulatory, and cultural systems:

- › **Respecting diverse standards:** MHRA, NMPA, and EU each frame compliance differently.
- › **Aligning incentives:** investors, regulators, and clinicians may prioritise different objectives.
- › **Shared accountability:** joint ESG monitoring frameworks can prevent misalignment.
- › **Patient-first decisions:** the ultimate measure of ESG is whether outcomes serve patients fairly in both ecosystems.



Practical Steps for SMEs & Founders

For SMEs and startups, ESG can feel abstract, but embedding it early builds credibility with partners and investors. Practical steps include:

- ✓ Embed ESG metrics in pitch decks and MoUs.
- ✓ Select CROs, service providers, and vendors with documented ESG commitments.
- ✓ Apply 'data ethics by design' in trials, especially AI-driven studies.
- ✓ Monitor diversity and inclusion across teams and partnerships.
- ✓ Report transparently on sustainability and patient outcomes.
- ✓ Build scalable ESG frameworks, including self-audits, to demonstrate progress.



EFEC's Role in Embedding ESG

EFEC maintains a dynamic network of independent, accredited ESG, legal, and regulatory experts in both the UK and China. All guidance is validated in direct collaboration with these specialists to ensure clients receive the most up-to-date, credible, and cost-effective advice and solutions.


Excellence First Enterprise Consultancy Ltd (EFEC) is not just an advisory body, but a values-driven catalyst for responsible growth in life sciences. Our contributions include:

- › **Partnership Design:** ensuring ESG is integrated into alliance structures and agreements.
- › **Talent Pipelines (CognateUK):** building a new generation of globally minded leaders trained in ESG principles.
- › **Innovation Hubs (UK–China Life Sciences Innovation Hub):** embedding ESG awareness in ecosystem projects from inception.




EFEC's mission is to ensure that cross-border ambition is matched with responsibility, fairness, and trust.

For founders and ecosystem leaders, ESG is now a non-negotiable differentiator. Embedding ESG not only improves compliance and credibility, it makes partnerships more resilient and impactful.

EFEC invites innovators, investors, and institutions to co-create ESG-centred pathways across the UK and China. Together, we can ensure that science serves patients and society while building sustainable, cross-border ecosystems.




Our three pillars



UK-China map with arrows showing collaborative ESG touchpoints (e.g., Cambridge ↔ Shanghai, Midlands ↔ Suzhou).

Founder-Facing Checklist

- ✓ Engage NMPA and provincial pilot authorities early.
- ✓ Select the right pilot zone for your product (Hainan = imports, Lingang = AI/real-world, Suzhou = biotech collabs).
- ✓ Partner with local CROs – bilingual, regulatory-savvy, trusted.
- ✓ Translate and localise all trial documentation.
- ✓ Budget realistically: CRO fees, site audits, translations, legal/IP.
- ✓ Secure IP in both UK and China before entry.
- ✓ Plan MHRA and NMPA pathways in parallel.
- ✓ Prioritise early regulator engagement and transparency.
- ✓ Involve EFEC as a bridge and interpreter – regulators respond better when intermediaries are trusted.



“In cross-border life sciences, **ESG is the difference** between short-term deals and long-term impact.”

Future releases of this guide may include quick-reference visuals for key regulatory bodies and pilot zones, to further support founder planning.

This toolkit is continually evolving. EFEC's support extends from strategy to negotiation, and upcoming visual enhancements will further simplify the founder journey.
References (for credibility)

Resources (verified October 2025)

NMPA (China National Medical Products Administration): www.nmpa.gov.cn/
MHRA (Medicines and Healthcare products Regulatory Agency): www.gov.uk/mhra
Hainan Baoao Lecheng Pilot Zone: en.ledicityhn.com/
Lingang New Area (Shanghai): en.lingang.gov.cn/
Suzhou Industrial Park (SIP): eng.sipac.gov.cn/

Official sources verified as of October 2025.
Please check regulator websites for the latest updates.